Catalog No.
Product Name
Application
Product Information
Citations
-
Conjugate Compound with PARP Inhibitor
ADP-ribose/PARP-IN-1 is a conjugated compound that combines disease-targeting moieties with PARP inhibitor functionality. This reagent selectively delivers PARP inhibitors to tumor cells, facilitating the inhibition of PARP enzymes that are critical for DNA damage repair. The presence of a cleavable linker ensures the release of the PARP inhibitor under specific conditions, while the chelator component enables the accumulation of radionuclides that exert cytotoxic effects. ADP-ribose/PARP-IN-1 is a valuable tool for research into prostate cancer and other malignancies characterized by PARP dependency. -
PARP Inhibitor
LT-626 is a potent poly(ADP-ribose) polymerase (PARP) inhibitor, with an IC50 of 1.60 nM. This inhibitor effectively reduces cellular poly(ADP-ribose) synthesis, demonstrating an EC50 of 17.9 nM, and displays enhanced cytotoxicity in colorectal cancer cells with MRE11 mutations. Additionally, LT-626 exhibits synergistic effects when combined with chemotherapeutic agents such as Cisplatin, Oxaliplatin, and SN-38, making it a valuable tool for colorectal cancer research applications. -
PARP7 Inhibitor
RBN010860 is a potent inhibitor of PARP7, exhibiting an IC50 value of less than 0.1 μM. This reagent serves as a valuable tool for investigating the role of PARP7 in cancer biology, enabling researchers to explore its potential as a therapeutic target in oncological studies. -
PARP7 Inhibitor
PARP7-IN-12 is a potent inhibitor of PARP7, exhibiting an IC50 value of 7.836 nM. This compound demonstrates significant potential in cancer research by modulating poly(ADP-ribose) polymerase activity, which is associated with DNA damage response pathways. PARP7-IN-12 may serve as an effective tool for elucidating the role of PARP7 in tumor biology and for developing therapeutic strategies targeting PARP-related pathways in cancer. -
PARP Inhibitor
PARP1-IN-6 is a dual inhibitor of tubulin and PARP-1, displaying IC50 values of 0.94 μM and 0.48 μM, respectively. This compound demonstrates significant biological activity by disrupting cellular processes mediated by both targets, making it a valuable tool for cancer research. PARP1-IN-6 is particularly useful in studies investigating the roles of PARP inhibition in DNA repair mechanisms and cytoskeletal dynamics. -
PARP1 Inhibitor
DPQ hydrochloride is a potent and selective inhibitor of PARP-1 (poly(ADP-ribose) polymerase 1), effectively blocking PARP-1-mediated DNA damage repair and reducing NAD+/ATP consumption. This compound demonstrates significant anti-inflammatory properties by inhibiting the activation of the NF-κB pathway, leading to a decrease in pro-inflammatory cytokines such as TNF-α and IL-6, as well as mitigating oxidative stress. DPQ hydrochloride is ideal for research applications related to inflammation and can be utilized in studies of conditions such as acute lung injury, myocardial infarction, and neurodegenerative diseases. -
PARP-1 Inhibitor
Lotixparib is a potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1), a key enzyme involved in DNA damage repair. This compound demonstrates cytoprotective effects, offering potential therapeutic applications in retinal diseases. Lotixparib is valuable for research focused on PARP-1-related conditions and mechanisms underlying DNA repair pathways. -
PARP1 PROTAC-type Degrader
Vrucaparib-TP4 is a PROTAC-type degrader that targets PARP1. It facilitates the ubiquitination and subsequent degradation of PARP1, making it a valuable tool in cancer research. This compound is particularly useful for investigating the role of PARP1 in tumor biology and evaluating therapeutic strategies that exploit the degradation pathway for potential anti-tumor effects. -
PARP7 Inhibitor
PARP7-IN-23 is a potent inhibitor of Poly(ADP-ribose) polymerase 7 (PARP7) with an EC50 of 0.915 nM for phosphorylated STAT1 (pSTAT1) in NCI-H1373 cells. This compound demonstrates significant inhibitory activity, which positions it as a valuable tool for cancer research, particularly in studies involving STAT1 signaling pathways and therapeutic interventions targeting PARP7. -
PARP1 Inhibitor
PARP1-IN-21 is a potent inhibitor of PARP1, exhibiting an IC50 of less than 10 nM. This compound effectively disrupts the poly(ADP-ribose) polymerase 1 enzymatic activity, leading to the inhibition of DNA repair processes. It is primarily utilized in research applications focused on cancer biology and therapeutic development, particularly in the exploration of combination therapies for tumors with defective homologous recombination. -
PARP1 Inhibitor
PARP1-IN-43 is a potent PARP1 inhibitor with an IC50 of 5 nM, exhibiting effective penetration across the blood-brain barrier. This compound is primarily utilized in research focused on homologous recombination-deficient central nervous system (CNS) tumors, facilitating the exploration of targeted therapies in oncology. Its ability to selectively inhibit PARP1 makes it a valuable reagent for investigating DNA repair mechanisms and their implications in cancer biology. -
PARP1 Inhibitor
PARP1-IN-39 is a potent inhibitor of PARP1, exhibiting an IC50 of 0.22 nM, and an IC50 of 1.57 nM in human breast cancer cells. This compound is valuable for investigating cancers associated with DNA repair deficiencies, including those linked to BRCA1/2 mutations, and is applicable in studies of breast, ovarian, pancreatic, and prostate cancers. PARP1-IN-39 facilitates research into targeted therapies that exploit the vulnerabilities of cancer cells with defective DNA repair mechanisms. -
PARP Inhibitor
KCL-440 is a potent PARP inhibitor that effectively penetrates the central nervous system, exhibiting an IC50 of 68 nM for PARP-1 inhibition. This compound is primarily utilized in research exploring DNA repair mechanisms, cancer therapy, and neurodegenerative disease models, making it a valuable tool for studying therapeutic strategies targeting cellular stress responses. -
PARP7 Probe
PARP7-probe-1 is a biotinylated chemiluminescent probe specifically designed to bind to the active site of PARP7. This reagent allows for the investigation of PARP7's enzymatic activity and its role in various biological processes. PARP7-probe-1 is suitable for applications involving protein interactions and the study of cellular mechanisms associated with PARP7 function. -
PARP7 Inhibitor
TIPARP-IN-1 is a selective inhibitor of PARP7 (TIPARP) with an IC50 of 2.15 nM. By inhibiting TIPARP, this compound restores the interferon signaling pathway in tumors, effectively enhancing the anti-tumor immune response within the tumor microenvironment while minimizing systemic cytokine production. TIPARP-IN-1 is an important tool for investigating the role of PARP7 in head and neck squamous cell carcinoma. -
PARP Inhibitor
4-Aminonaphthalimide is a potent inhibitor of poly(ADP-ribose) polymerase (PARP), a key enzyme involved in DNA repair processes. This compound enhances the cytotoxic effects of γ-radiation in cancer cells, making it a valuable tool for studies focused on cancer therapy and radiation biology. Its dual function as a PARP inhibitor and radiation sensitizer positions 4-Aminonaphthalimide as an important reagent for research applications in oncology and therapeutic resistance. -
PARP1 Inhibitor
PARP1-IN-51 is a potent inhibitor of the enzyme PARP1, which plays a critical role in DNA repair mechanisms. This compound exhibits significant biological activity by disrupting the PARP1-mediated repair of single-strand breaks, ultimately leading to cancer cell apoptosis. PARP1-IN-51 is particularly valuable for research in oncology, including studies focused on breast cancer and other malignancies with defective DNA repair pathways. -
PARP1/2 Inhibitor
PARP1-IN-37 is a selective inhibitor of poly(ADP-ribose) polymerases 1 and 2 (PARP1/2), exhibiting an IC50 of 24 nM for PARP1. This compound effectively inhibits PARP activity in cellular assays with an EC50 of 3.7 μM. PARP1-IN-37 is particularly relevant for investigations into BRCA-mutated tumors, including breast and ovarian cancers, making it a valuable tool for cancer research and therapeutic development. -
PARP1 Inhibitor
PARP1-IN-18 is a potent inhibitor of the poly(ADP-ribose) polymerase 1 (PARP1) enzyme, demonstrating an IC50 value of 2.7 nM. This compound exhibits significant anticancer activity, making it a valuable tool for research applications targeting DNA repair mechanisms and cancer therapeutics. PARP1-IN-18 can be utilized to explore PARP-mediated cellular processes and evaluate its potential in combination therapies for various malignancies. -
PARP7 Inhibitor
PARP7-IN-24 is a highly potent inhibitor of PARP7, exhibiting an EC50 of 0.375 nM for pSTAT1 in NCI-H1373 cells. This compound is poised for significant contributions to cancer research, facilitating the study of PARP7's role in tumor biology and potential therapeutic interventions. Its strong inhibitory activity makes it a valuable tool for exploring the molecular mechanisms underlying cancer progression and treatment responses. -
PARP-1 Inhibitor
PARP-1-IN-23 is a selective inhibitor of poly(ADP-ribose) polymerase 1 (PARP-1), exhibiting an IC50 of 12.38 nM. This compound demonstrates significant antitumor activity in vivo, making it a valuable tool for studying the mechanisms of cancer progression and treatment. Its inhibition of PARP-1 suggests potential applications in enhancing the efficacy of chemotherapy and targeting cancer cell survival pathways. -
PARP1/2 Inhibitor
Senaparib hydrochloride is a selective inhibitor of PARP1 and PARP2, demonstrating significant anti-tumor activity. This compound is particularly effective in the treatment of advanced ovarian cancer, making it relevant for research focused on cancer therapeutics and mechanisms of tumor progression. Its ability to interfere with DNA repair pathways positions Senaparib hydrochloride as a valuable tool in understanding the efficacy of PARP inhibition in oncology. -
PARP Inhibitor
PARP-2/1-IN-2 is a potent inhibitor of poly (ADP-ribose) polymerases 1 and 2, exhibiting Kis of 2 nM and 5 nM, respectively. It demonstrates a biological activity with an EC50 of 3 nM in cell-based assays assessing PARP activity. This compound is valuable for research focused on cancer therapeutics, DNA repair mechanisms, and the role of PARP in various cellular processes. -
PARP Inhibitor
PARP1-IN-28 is a potent inhibitor of Poly(ADP-ribose) polymerase 1 (PARP1), a crucial enzyme involved in DNA repair and cellular response to stress. This compound exhibits significant anti-proliferative activity and is particularly relevant in cancer research, enabling studies on tumor cell viability and resistance mechanisms. Its application extends to assessing the efficacy of combination therapies in oncology, particularly in contexts involving homologous recombination deficiency. -
PARP1/2 Inhibitor
PARP1/2-IN-4 is a selective inhibitor of PARP1 and PARP2 enzymes, which play crucial roles in DNA repair processes via the base excision repair pathway. This compound exhibits significant potential in preclinical research for cancer therapy by enhancing the efficacy of DNA-damaging agents and promoting synthetic lethality in tumors with deficient DNA repair mechanisms. It is a valuable tool for studying DNA repair pathways and evaluating therapeutic strategies in oncology research. -
PARP10 Inhibitor
PARP10-IN-2 is a selective inhibitor of the mono-ADP-ribosyltransferase PARP10, exhibiting an IC50 of 3.64 µM in human PARP10 assays. This compound also effectively inhibits PARP2 and PARP15, with IC50 values of 27 µM and 11 µM, respectively. PARP10-IN-2 is valuable for research applications focusing on cellular processes influenced by ADP-ribosylation and has potential implications in cancer and neurodegenerative disease studies. -
PARP7 Inhibitor
KMR-206 is a selective inhibitor of PARP7, demonstrating an IC50 of 13.7 nM. This compound enhances the activation of STAT1 and phosphorylated STAT1, thereby promoting type I interferon signaling through STING degradation. KMR-206 exhibits notable anticancer activity, particularly against lung adenocarcinoma, and serves as a valuable tool for investigating its effects in colon cancer research. -
PARP Inhibitor
YCH1899 is an orally active PARP inhibitor, demonstrating a potent IC50 of less than 0.001 nM for PARP1/2. This compound exhibits significant antiproliferative effects against Capan-1 cells resistant to Olaparib and Talazoparib, with IC50 values of 0.89 nM and 1.13 nM, respectively. YCH1899 also presents favorable pharmacokinetic properties in rat models, making it a valuable tool for research in cancer therapeutics and resistance mechanisms. -
PARP-1 Inhibitor
PARP1-IN-29 is a potent PARP-1 inhibitor with an IC50 of 6.3 nM, demonstrating strong efficacy in modulating DNA damage repair pathways. Labeled with [18F], this compound is suitable for positron emission tomography (PET) imaging, allowing for targeted visualization of PARP-1 activity in tumors. Its applications extend to oncology and imaging research, providing valuable insights into cancer biology and treatment response. -
PARP-1 Inhibitor
5-AIQ (5-Aminoisoquinolin-1-one) is a selective inhibitor of PARP-1, a key protein involved in DNA repair mechanisms. This compound exhibits significant potential in reducing tissue injury resulting from ischemia-reperfusion of the liver. 5-AIQ is useful for research applications focused on understanding ischemia-reperfusion injury and developing therapeutic strategies for liver protection. -
PARP Inhibitor
UKTT15 is an allosteric inhibitor of the enzyme PARP1. It exhibits significant inhibitory activity against PARP1, influencing DNA repair mechanisms and cellular response to DNA damage. UKTT15 is useful in research focused on cancer biology, particularly in studies evaluating the therapeutic potential of PARP inhibition in cancer treatment and the modulation of DNA repair pathways. -
PARP-1/ARTD-1 Inhibitor
EB-47 is a selective inhibitor of PARP-1 (ARTD-1) with an IC50 value of 45 nM, demonstrating its strong inhibition profile. It also exhibits modest potency against ARTD5 with an IC50 of 410 nM. Structurally, EB-47 mimics the substrate NAD+, extending from the nicotinamide to the adenosine subsite, making it a valuable tool for studying DNA repair mechanisms and related cancer research applications. -
PARP Inhibitor
AZ3391 is a selective inhibitor of the PARP enzyme family, which is critically involved in cellular processes including DNA repair, chromatin remodeling, and cell cycle regulation. As a quinoxaline derivative, AZ3391 demonstrates significant potential for investigating neurodegenerative diseases and conditions affecting the central nervous system, particularly in the brain and spinal cord. This compound is valuable for research applications focused on understanding the mechanisms underlying DNA damage response and related pathologies. -
PARP-1 Inhibitor
Amelparib is a selective inhibitor of PARP-1, exhibiting potent activity with an IC50 of 18.5 nM for PARP-1 inhibition and 10.7 nM for cellular PAR formation. This orally active and water-soluble compound demonstrates potential neuroprotective effects, making it a valuable tool for research in the field of acute ischemic stroke. Amelparib's ability to modulate PARP-1 activity offers insights into its therapeutic roles in neuroprotection and cellular repair mechanisms. -
PARP Inhibitor
PARP1-IN-7 is a selective inhibitor of poly(ADP-ribose) polymerase-1 (PARP1), primarily functioning to disrupt DNA repair mechanisms in cancer cells. By inhibiting PARP1 activity, it enhances the cytotoxic effects of DNA-damaging agents, making it a valuable tool in cancer research. Its applications include studying mechanisms of tumorigenesis, evaluating synthetic lethality in cancer therapies, and exploring potential combinations with other anticancer agents. -
PARP Inhibitor
E7016 is a potent orally bioavailable inhibitor of PARP (Poly(ADP-ribose) polymerase). By inhibiting DNA repair mechanisms, E7016 enhances the radiosensitivity of tumor cells both in vitro and in vivo, making it a promising candidate for cancer therapeutics. This compound is useful in research applications focused on cancer treatment strategies involving DNA damage response and repair pathways. -
PARP Inhibitor
ART-IN-1 is a selective inhibitor of poly(ADP-ribose) polymerases (PARPs), with IC50 values of 19 µM for PARP2, 22 µM for TNKS2, 2.4 µM for PARP10, greater than 100 µM for PARP14, and 1.1 µM for PARP15. This compound is utilized in research focused on DNA damage repair mechanisms and cancer therapeutics, making it a valuable tool for studying PARP-related pathways and their implications in various diseases. ART-IN-1 is instrumental in elucidating the role of PARP inhibition in enhancing the efficacy of chemotherapy and targeted therapies. -
USP1/PARP1 Inhibitor
KSQ-4279 (gentisate) is a potent inhibitor of USP1 and selectively targets PARP1. This compound demonstrates significant potential in cancer research, showcasing its ability to disrupt key pathways involved in tumor progression and repair mechanisms. Its unique inhibitory properties make it a valuable tool for studying the molecular underpinnings of various cancer types and developing targeted therapeutic strategies. -
PARP1/2 Inhibitor
iVeliparib-AP6 is a proteolysis-targeting chimera (PROTAC) that functions as a potent inhibitor of PARP1 and PARP2. It demonstrates DC50 values for PARP1 and PARP2 degradation at 36 nM and 63 nM, respectively, with IC50 values of 69 nM and 21 nM. The compound contains a Veliparib-based PARP inhibitor warhead linked to a CRBN E3 ligase binder, utilizing Thalidomide to recruit CRBN E3 ubiquitin ligase, thereby facilitating effective degradation of PARP2. This innovative mechanism positions iVeliparib-AP6 as a valuable tool for studying PARP-related pathways and therapeutic strategies in cancer research. -
PARP-1 Inhibitor
PARP-1-IN-4 is a selective inhibitor of PARP-1, exhibiting an IC50 value of 302 μM. This compound is utilized in research focused on lung adenocarcinoma, where inhibiting PARP-1 activity may contribute to understanding cancer pathophysiology and therapeutic strategies. Its specificity for PARP-1 makes it a valuable tool in studying DNA repair mechanisms and their impact on cancer cell proliferation and survival. -
ARTD3/PARP3 Inhibitor
ARTD3/PARP3-IN-1 is an unselective inhibitor targeting diphtheria toxin-like ADP-ribosyltransferase 3 (ARTD3) and PARP3. This compound modulates ADP-ribosylation processes, influencing cellular responses to DNA damage and stress. It is primarily used in research applications investigating the roles of ARTD3 and PARP3 in cellular signaling, cell survival, and cancer biology. -
PARP-1 Inhibitor
LS-75 is a potent inhibitor of PARP-1, exhibiting an IC50 value of 18 μM and demonstrating blood-brain barrier permeability. This compound is recognized for its neuroprotective properties, making it a valuable tool for research in neurodegenerative diseases and cellular response to DNA damage. Its selective inhibition of PARP-1 activity lends itself to investigations of therapeutic strategies aimed at neurological health and related disorders. -
PARP Inhibitor
Rucaparib tartrate is a potent inhibitor of PARP proteins, specifically targeting PARP-1, PARP-2, and PARP-3, with a Ki value of 1.4 nM for PARP-1. This compound also exhibits modest inhibitory activity against hexose-6-phosphate dehydrogenase (H6PD). Rucaparib tartrate is primarily utilized in research related to castration-resistant prostate cancer (CRPC), making it a valuable reagent for studies involving DNA repair mechanisms and cancer therapeutics. -
PARP-1 Inhibitor
PARP1-IN-5 is a potent and selective inhibitor of PARP-1, exhibiting an IC50 of 14.7 nM. This compound demonstrates low toxicity and is orally active, making it suitable for in vivo studies. PARP1-IN-5 is primarily used in cancer research to elucidate the role of PARP-1 in DNA repair mechanisms and its potential as a therapeutic target in oncology. -
PARP Inhibitor
Venadaparib hydrochloride is a potent and selective inhibitor of poly(ADP-ribose) polymerase (PARP) with demonstrated anticancer activity. This compound is primarily utilized in research focused on solid tumors, aiding in the exploration of cancer therapies targeting DNA repair mechanisms. -
PARP Inhibitor
Rucaparib acetate is a potent oral inhibitor of PARP proteins, primarily PARP-1, with a Ki of 1.4 nM. By targeting PARP-1, PARP-2, and PARP-3, Rucaparib acetate induces synthetic lethality in cancer cells with defective homologous recombination. Its unique profile also includes modest inhibition of hexose-6-phosphate dehydrogenase (H6PD). This reagent is applicable in research for castration-resistant prostate cancer (CRPC) and other malignancies characterized by DNA repair deficiencies. -
PARP Inhibitor
Rucaparib hydrochloride is a potent, orally active inhibitor of PARP proteins, specifically targeting PARP-1, PARP-2, and PARP-3, with a Ki value of 1.4 nM for PARP-1. In addition to its principal function as a PARP inhibitor, Rucaparib exhibits modest inhibitory activity toward hexose-6-phosphate dehydrogenase (H6PD). This compound is primarily utilized in research focused on castration-resistant prostate cancer (CRPC), contributing to studies aimed at better understanding and overcoming resistance mechanisms in cancer therapy. -
PARP Inhibitor
Mefuparib is a potent poly ADP-ribose polymerase (PARP) inhibitor that demonstrates significant brain penetration attributed to its high protein binding affinity. This compound is utilized in cancer research to investigate the therapeutic potential of PARP inhibition in various malignancies. Its ability to interfere with DNA repair mechanisms makes it a valuable tool for studying tumor biology and treatment resistance. -
PARP7 Inhibitor
PARP7-IN-19 is a potent inhibitor of PARP7, exhibiting an IC50 of less than 10 nM. This compound is valuable for research focused on the role of PARP7 in tumor biology, enabling investigations into cancer progression and therapeutic targeting. Its high specificity makes it an important tool for studying the mechanisms underlying PARP7-related pathways in various cancer models. -
PARP Inhibitor
Lerzeparib is a potent inhibitor of poly(ADP-ribose) polymerase (PARP), demonstrating significant antineoplastic activity. By obstructing the PARP enzyme, Lerzeparib effectively disrupts DNA repair mechanisms in cancer cells, leading to increased cellular apoptosis. This compound is primarily utilized in cancer research to explore therapeutic strategies for tumors with homologous recombination deficiencies, such as BRCA-mutated cancers.
